Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 4

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 15
Chunk 4
---
110.30#Letter Agreement, dated as of December 5, 2022, between the Registrant and Tsveta Milanova10-K001-36014February 23, 202310.3810.31#Form of Inducement Stock Option Agreement for Tsveta MilanovaS-8333- 269018January 3, 202399.110.32#Form of Inducement Restricted Stock Unit Agreement for Tsveta MilanovaS-8333- 269108January 3, 202399.210.33#**Form of Inducement Performance Stock Unit Agreement for Tsveta MilanovaS-8333- 269108January 3, 202399.310.34#2023 Stock Incentive PlanS-8333-272615June 13, 202399.110.35#Form of Stock Option Agreement Under 2023 Stock Incentive Plan10-Q001-36014August 3, 202310.210.36#Form of Restricted Stock Unit  Agreement Under 2023 Stock Incentive Plan10-Q001-36014August 3, 202310.310.37#Form of Restricted Stock Unit  Agreement (Performance-Based) Under 2023 Stock Incentive Plan10-Q001-36014August 3, 202310.410.38**Purchase and Sale Agreement, dated May 24, 2024, by and between the Registrant and Royalty Pharma Investments 2019 ICAV10-Q001-36014August 1, 202410.119.1Insider Trading PolicyX21.1Subsidiaries of the RegistrantX23.1Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting FirmX31.1Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amendedX31.2Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.X32.1*Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X

88

32.2*Certification of principal financial officer pursuant to 18 U.S.C. §1350,